Effects of DAP on diaphragm force and fatigue, including fatigue due to neurotransmission failure

Journal of Applied Physiology

Volumn 81, Issue 5, 1996, Pages 2214-2220

  Van Lunteren, Erik ^a,b   Moyer, Michelle ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

3,4 diaminopyridine; contractility; potassium channel; respiratory muscle; skeletal muscle

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM MUSCLE; MUSCLE CONTRACTILITY; MUSCLE CONTRACTION; MUSCLE EXCITATION; MUSCLE FATIGUE; MUSCLE FORCE; NEUROTRANSMISSION; NONHUMAN; PHRENIC NERVE; PRIORITY JOURNAL; RAT;

EID: 0029844222     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.1996.81.5.2214     Document Type: Article

References (33)

1. Aldrich, T., A. Shander, I. Chaudhry, and H. Nagashima. Fatigue of isolated rat diaphragm: role of impaired neuromuscular transmission. J. Appl. Physiol. 61: 1077-1083, 1986.
2. Allen, D., J. Lee, and H. Westerblad. Intracellular calcium and tension during fatigue in isolated single muscle fibres from Xenopus laevis. J. Physiol. Lond. 415: 433-458, 1989.
3. Asmussen, E. Muscle fatigue. Med. Sci. Sports 11: 313-321, 1979.
4. Bever, C., J. Leslie, D. Camenga, H. Panitch, and K. Johnson. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann. Neurol. 27: 421-427, 1990.
5. Bowman, W., C. Harvey, and I. Marshall. The actions of aminopyridines on avian muscle. Naunyn-Schmiedeberg's Arch. Pharmacol. 297: 99-103, 1977.
6. Delbono, O., and B. Kotsias. Relation between action potential duration and mechanical activity on rat diaphragm fibers. Pfluegers Arch. 410: 394-400, 1987.
7. Durant, N., and I. Marshall. The effects of 3,4-diaminopyridine on acetylcholine release at the frog neuromuscular junction. Eur. J. Pharmacol. 67: 201-208, 1980.
8. Durant, N., and I. Marshall. The effects of 3,4-diaminopyridine on spontaneous and evoked transmitter release at the frog neuromuscular junction (Abstract). J. Physiol. Lond. 280: 21P, 1978.
9. Harvey, A., and I. Marshall. A comparison of the effects of aminopyridines on isolated chicken and rat skeletal muscle preparations. Comp. Biochem. Physiol. C Comp. Pharmacol. 58: 161-165, 1977.
10. Harvey, A., and I. Marshall. The actions of three diaminopyridines on chick biventer cervicis muscle. Eur. J. Pharmacol. 44: 303-309, 1977.
11. Heuser, J. Synaptic vesicle exocytosis revealed in quick-frozen frog neuromuscular junction treated with 4-aminopyridine and given a single electric shock. In: Approaches to the Cell Biology of Neurons, edited by W. Conan and J. Perrendelli. Bethesda, MD: Soc. Neurosci., 1977, p. 215-239. (Soc. Neurosci. Symp. 2)
12. Katz, B., and R. Miledi. Estimates of quantal content during "chemical potentiation" of transmitter release. Proc. R. Soc. Lond. B 205: 369-378, 1979.
13. Kim, Y., M. Goldner, and D. Prat. Facilitatory effects of 4-aminopyridine on normal neuromuscular transmission. Muscle Nerve 3: 105-111, 1980.
14. Kirsch, G., and T. Narahashi. 3,4-Diaminopyridine: a potent new potassium channel blocker. Biophys. J. 22: 507-512, 1978.
15. Kuei, J., R. Shadmehr, and G. Sieck. Relative contribution of neurotransmission failure to diaphragm fatigue. J. Appl. Physiol. 68: 174-180, 1990.
16. Lin-Shiau, S., S. Day, and W. Fu. Use of ion channel blockers in studying the regulation of skeletal muscle contractions. Naunyn-Schmiedeberg's Arch. Pharmacol. 344: 691-697, 1991.
17. Lundh, H. Effects of 4-aminopyridine on neuromuscular transmission. Brain Res. 153: 307-318, 1978.
18. Lundh, H., S. Leander, and S. Thesleff. Antagonism of the paralysis produced by botulinum toxin in the rat. J. Neurol. Sci. 32: 29-43, 1977.
19. Lundh, H., and S. Thesleff. The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals. Eur. J. Pharmacol. 42: 411-412, 1977.
20. Matsumoto, M., and W. Riker. Effects of several aminopyridines and analogs on calcium dependence of synaptic transmission. J. Pharmocol. Exp. Ther. 228: 573-578, 1984.
21. McEvoy, K., A. Windebank, J. Daube, and P. Low. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N. Engl. J. Med. 321: 1567-1571, 1989.
22. Molgo, J., M. Lemeignan, and P. Lechat. Effects of 4-aminopyridine at the frog neuromuscular junction. J. Pharmacol. Exp. Ther. 203: 653-663, 1977.
23. Molgo, J., M. Lemeignan, and P. Lechat. Analysis of the action of 4-aminopyridine during repetitive stimulation at the neuromuscular junction. Eur. J. Pharmacol. 53: 307-311, 1979.
24. Molgo, J., H. Lundh, and S. Thesleff. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur. J. Pharmacol. 61: 25-34, 1980.
25. Murray, N., and J. Newsom-Davis. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 31: 265-271, 1981.
26. Prabhakar, N., J. Mitra, J. Overholt, and N. Cherniack. Analysis of postinspiratory activity of phrenic motoneurons with chemical and vagal reflexes. J. Appl. Physiol. 61: 1499-1509, 1986.
27. + on the recovery of the twitch and tetanic force following fatigue in the sartorius muscle of the frog, Rana pipiens. J. Muscle Cell Res. Motil. 15: 420-431, 1994.
28. Thesleff, S. Commentary: aminopyridines, and synaptic transmission. Neuroscience 5: 1413-1419, 1980.
29. Thomsen, R., and D. Wilson. Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J. Pharmocol. Exp. Ther. 227: 260-265, 1983.
30. + channel blockade on fatigue in rat diapragm muscle. J. Appl. Physiol. 79: 738-747, 1995.
31. Van Lunteren, E., and H. Vafaie. Force potentiation in respiratory muscles: comparison of diaphragm and sternohyoid. Am. J. Physiol. 264 (Regulatory Integrative Comp. Physiol. 33): R1095-R1100, 1993.
32. + channel blockade. Respir. Physiol. 99: 331-340, 1995.
33. Vohra, M., and S. Pradhan. Pharmacology of 3,4-diaminopyridine. Arch. Int. Pharmacol. 150: 413-424, 1964.